Introduction: The availability of targeted therapies has transformed the management of advanced NSCLC; however, the majority of patients do not undergo guideline-recommended tumor genotyping. The impact of plasma-based next-generation sequencing (NGS) performed simultaneously with diagnostic biopsy in suspected advanced NSCLC has largely been unexplored... Conclusions: Plasma-based NGS performed at the time of diagnostic biopsy in patients with suspected advanced NSCLC is associated with decreased time-to-treatment compared to usual care. READ ARTICLE
JTO Clinical and Research Reports DOI:10.1016/j.jtocrr.2022.100301
Authors: J. C. Thompson, C. Aggarwal, J. Wong, V. Nimgaonkar, W. Hwang, M. Andronov, D. M. Dibardino, C. T. Hutchinson, K. C. Ma, Lanfranco, E. Moon, A. R. Haas, A. P. Singh, C. A. Ciunci, M. Marmarelis, C. D’Avella, J. V. Cohen, J. M. Bauml, R. B. Cohen, C. J. Langer, A. Vachani, E. L. Carpenter